Literature DB >> 16421727

Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.

J Thiele1, H M Kvasnicka.   

Abstract

Controversy continues to exist regarding not only the exact definition and grading of myelofibrosis (MF), but also whether, and to what extent, this feature may be correlated with clinical findings. A retrospective study was performed involving 865 bone marrow (BM) biopsies together with the clinical records from patients with chronic idiopathic myelofibrosis (CIMF). Diagnosis was established according to the World Health Organization criteria, and assessment of MF followed a consensus scoring system that included four grades (MF-0 to MF-3). Histopathological and clinical evaluations were carried out in an independent fashion. Prefibrotic and early CIMF (MF-0/-1) were presented by 565 patients showing borderline to mild anemia and no or slight splenomegaly, but frequently, thrombocytosis exceeding 500x10(9)/l was shown. In 300 patients, manifest reticulin and collagen fibrosis (MF-2/-3) were characterized by marked anemia, gross splenomegaly, peripheral blasts, and normal to decreased platelet and leukocyte counts. The latter cohort was consistent with findings generally in keeping with MF with myeloid metaplasia. Regarding the stepwise evolution of disease, sequential BM examinations showed that in 103 patients, prefibrotic and early CIMF transformed into advanced stages accompanied by correspondingly developing clinical and histomorphological features. Survival analysis (univariate calculation) revealed a significantly more favorable prognosis in prefibrotic vs advanced stages of CIMF. On the other hand, higher classes of MF also exerted a higher clinical risk profile (Lille score). In conclusion, the dynamics of the disease process in CIMF are characterized by evolving MF in the BM and closely associated changes of relevant hematological findings.

Entities:  

Mesh:

Year:  2006        PMID: 16421727     DOI: 10.1007/s00277-005-0042-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  27 in total

Review 1.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 2.  The bone marrow stroma in hematological neoplasms--a guilty bystander.

Authors:  Claudio Tripodo; Sabina Sangaletti; Pier P Piccaluga; Sonam Prakash; Giovanni Franco; Ivan Borrello; Attilio Orazi; Mario P Colombo; Stefano A Pileri
Journal:  Nat Rev Clin Oncol       Date:  2011-03-29       Impact factor: 66.675

3.  Myelofibrosis osteoclasts are clonal and functionally impaired.

Authors:  Ivo Veletic; Taghi Manshouri; Asha S Multani; C Cameron Yin; Lei Chen; Srdan Verstovsek; Zeev Estrov
Journal:  Blood       Date:  2019-02-11       Impact factor: 22.113

4.  The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

Authors:  Bin Fu; Chi Young Ok; Maitrayee Goswami; Wei Xei; Jesse M Jaso; Tariq Muzzafar; Carlos Bueso-Ramos; Srdan Verstovsek; Guillermo Garcia-Manero; L Jeffrey Medeiros; Sa A Wang
Journal:  Ann Hematol       Date:  2013-05-10       Impact factor: 3.673

5.  The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.

Authors:  Grzegorz Helbig; Agata Wieczorkiewicz; Krzysztof Woźniczka; Katarzyna Wiśniewska-Piąty; Anna Rusek; Sławomira Kyrcz-Krzemień
Journal:  Med Oncol       Date:  2012-03-01       Impact factor: 3.064

6.  Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis.

Authors:  Danijela Lekovic; Mirjana Gotic; Maja Perunicic-Jovanovic; Ana Vidovic; Andrija Bogdanovic; Gradimir Jankovic; Vladan Cokic; Natasa Milic
Journal:  Med Oncol       Date:  2014-02-06       Impact factor: 3.064

7.  The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading.

Authors:  O Pozdnyakova; S Rodig; S Bhandarkar; K Wu; J Thiele; R Hasserjian
Journal:  Leukemia       Date:  2014-09-03       Impact factor: 11.528

8.  Platelet derived growth factor receptor-beta (PDGFRβ) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibrosis.

Authors:  Judit Bedekovics; Attila Kiss; Lívia Beke; Katalin Károlyi; Gábor Méhes
Journal:  Virchows Arch       Date:  2013-06-08       Impact factor: 4.064

Review 9.  Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.

Authors:  Minas P Economides; Srdan Verstovsek; Naveen Pemmaraju
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

10.  Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis.

Authors:  Aziz Nazha; Zeev Estrov; Jorge Cortes; Carlos E Bueso-Ramos; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.